Uniting Preclinical Innovation, GMP-Ready Manufacturing & Regulatory Clarity to Accelerate Scalable, Clinically Successful iPSC Therapies Across Parkinsons, Diabetes, Oncology & More
The 6th iPSC Drug Development Summit is the only meeting exclusively focused on advancing iPSC-based cell therapies, end-to-end. It brings together leaders such as Aspen Neuroscience, BlueRock Therapeutics, and Vertex Pharmaceuticals, who are building programs today, spanning discovery, preclinical development, process development, CMC, and regulatory strategy, to ensure iPSC therapies are designed for scale and clinical success from the very beginning.
After years of uncertainty, the field is re-emerging on the 20th anniversary of iPSC technology, with stronger clinical data than ever before from Century Therapeutics advancing their Type 1 diabetes program into the clinic, and positive data for BlueRock Therapeutics advancing to phase III.
With investment at its strongest point in years, with the likes of Aspen Neuroscience and Century Therapeutics securing $100 million plus in funding rounds, the focus has shifted decisively from promise to performance. The teams that get execution right now will define the next decade of iPSC therapy development.
Companies in the field now are committed to moving into the clinic and focused on delivering to the patient. As attention shifts toward scalability, quality, and regulatory alignment, this summit provides the forum for biopharma, investment, and solution providers to unite and accelerate the transition from research to real world therapies.
If you’re serious about iPSC drug development, this is a must attend meeting!
I enjoyed all the speakers, great agenda, and the ease of connecting with people. The speed networking session was good!
Director PSC Biology, BlueRock Therapeutics
The talks were high quality and well organized. It was valuable to hear diverse perspectives on iPSC applications, and the networking opportunities stood out.
Professor Medical & Health, Harvard Medical School
I thought it was a nice mix of vendors and key stakeholders from companies of interest in the field. Good discussions and the right amount of time set aside for socializing in the vendor area, lunches, and at posters. Overall nice atmosphere.
Director, Voyager Therapeutics
Explore the Full Event Guide
- 25+ Industry leading speakers
- End-to-end coverage of iPSC drug development
- 2 dedicated tracks on preclinical development and process development and CMC
- Unrivaled Networking Opportunities with Clinical Companies Securing Investment
- See why this is the must-attend meeting for iPSC development
Official Partners
Lead Partner
Expertise Partners
Program Partner
Innovation Partner
Attending Companies Include
Explore the Agenda
See where the bottlenecks really are and how teams are solving them.
This agenda goes beyond theory to highlight the decisions shaping real iPSC programs, from line selection and genome integrity to late stage scale up, comparability, and regulatory confidence.
Partner With Us
Shape the discussion at the point where priorities are being set.
This summit brings together the companies actively advancing iPSC therapies. Partnering here places your organization at the center of conversations that translate into program and collaborations.
Join the iPSC Community
Connect with a field that has moved past experimentation.
Meet a focused community of leaders working through the realities of clinical translation, manufacturing scale, and regulatory alignment. Biopharma and academics attend for free!